Peer-reviewed veterinary case report
Survival in dogs with mitral valve heart failure
By de Madron, Eric et al.·Published in The Canadian veterinary journal = La revue veterinaire canadienne·2011·Alta Vista Animal Hospital, Canada·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases.
- Species:
- dog
Plain-English summary
A group of 21 dogs with congestive heart failure (CHF) caused by mitral valve disease were treated with a combination of medications, including furosemide and pimobendan. The dogs had a median survival time of about 14 months after starting treatment. The study found that higher initial doses of furosemide and certain echocardiographic measurements were linked to shorter survival times. Overall, the combination of these medications helped many dogs live longer, even with moderate to severe heart issues.
People also search for: dog congestive heart failure treatment · mitral valve disease in dogs · furosemide dosage for dogs · pimobendan for dogs heart disease
Abstract
This retrospective study reports the survival time [onset of congestive heart failure (CHF) to death from any cause] of 21 dogs with mitral regurgitation (MR) and CHF treated with a combination of furosemide, angiotensin-converting enzyme inhibitor (ACEI, benazepril, or enalapril), pimobendan, spironolactone, and amlodipine. Baseline echocardiographic data: end-systolic and end-diastolic volume indices (ESVI and EDVI), left atrium to aorta ratio (LA/Ao), and regurgitant fraction (RF) are reported. Median survival time (MST) was 430 d. Initial dosage of furosemide (P = 0.0081) and LA/Ao (P = 0.042) were negatively associated with survival. Baseline echocardiographic indices (mean ± standard deviation) were 40.24 ± 16.76 for ESVI, 161.48 ± 44.49 mL/m(2) for EDVI, 2.11 ± 0.75 for LA/Ao, and 64.71 ± 16.85% for RF. Combining furosemide, ACEI, pimobendan, spironolactone, and amlodipine may result in long survival times in dogs with MR and CHF. Severity of MR at onset of CHF is at least moderate.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22547843/